Startup profile · funding coverage
Canid funding, valuation and investors
Scan-and-go vaccine operations platform for independent pediatric practices.
Keep track of Canid
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$10M · June 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$10M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · New York, NY
Overview
Canid streamlines pediatric vaccine programs by integrating with EHRs to automate ordering, inventory, billing, and public-health reporting. Founded by Pedro Sánchez de Lozada after seeing challenges in his family's pediatric practices, the NYC company raised $10M Series A in June 2025 led by Telescope Partners with FJ Labs and Brooklyn Bridge Ventures participating, bringing total funding to $12.9M. Canid serves 150+ pediatricians across 12 states per Business Wire.
Why Canid is interesting
Vaccines are the second-largest pediatric practice expense yet most clinics break even or lose money — Canid turns a barcode scan into outsourced vaccine ops.
Product & use cases
EHR-integrated platform where pediatricians scan a vaccine barcode and Canid handles inventory, reimbursement, compliance reporting, and outreach automation.
- Outsourced vaccine inventory and billing for small pediatrics
- AI-assisted EHR integration across clinic systems
- Patient outreach to close vaccination gaps
Key facts
- Series A (Jun 2025): $10M; total $12.9M
- 150+ pediatricians, 300K+ children in panels
- Started with COVID vaccines, expanded to all vaccines 2022
- Endpoints News: 69% of pediatricians break even or lose on vaccines
Funding history (newest first)
Series A
2025-06 $10M- Telescope Partners (lead)
- FJ Labs (participant)
- Brooklyn Bridge Ventures (participant)
Investors in our directory
Funds linked from Canid's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Vertical focus on vaccine economics with guaranteed payments and inventory risk transfer — not generic practice management.
Pediatric vaccine programs are operationally brutal at small scale; Canid's model only works if reimbursement automation beats in-house staff costs. Expansion depends on EHR integration depth and payer relationships.
-
EHR-native vaccine modules incumbent
Built-in EHR workflows without outsourced inventory.
-
Vaccine distributors (McKesson, etc.) adjacent
Supply chain without full admin automation.
-
Pediatric practice consultants alternative
Manual billing and inventory management.
Notable stories
- Sánchez de Lozada told Endpoints Canid began during COVID vaccine distribution before expanding to routine immunizations in 2022.
- Canid reported a 12% drop in vaccinations across its network Q1 2024 vs Q1 2025 amid broader hesitancy trends.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Canid's financing or category context.
FAQs about Canid
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.